{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T17:42:15Z","timestamp":1792172535052,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Imaging"],"DOI":"10.1186\/s12880-025-01824-9","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T16:00:54Z","timestamp":1752249654000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The clinical benefits of [18F]AlF-NOTA-octreotide PET\/CT in staging and restaging patients with gastroenteropancreatic neuroendocrine neoplasms: comparison of [18F]FDG PET\/CT"],"prefix":"10.1186","volume":"25","author":[{"given":"Donghe","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenfeng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guolin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjiao","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunting","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinhui","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"12","key":"1824_CR1","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","volume":"19","author":"B Oronsky","year":"2017","unstructured":"Oronsky B, Ma PC, Morgensztern D, Carter CA. Nothing but NET: a\u2002review\u2002of\u2002neuroendocrine\u2002tumors and carcinomas. Neoplasia. 2017;19(12):991\u20131002.","journal-title":"Neoplasia"},{"issue":"Suppl 1","key":"1824_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1159\/000080731","volume":"80","author":"BG Taal","year":"2004","unstructured":"Taal BG, Visser OEpidemiology\u2002of\u2002neuroendocrine\u2002tumours. Neuroendocrin- Ology. 2004;80(Suppl 1):3\u20137.","journal-title":"Neuroendocrin- Ology"},{"issue":"2","key":"1824_CR3","doi-asserted-by":"publisher","first-page":"717","DOI":"10.3390\/jcm12020717","volume":"12","author":"A Zappi","year":"2023","unstructured":"Zappi A, Persano I, Galvani L, Parlagreco E, Andrini E, Campana D, Brizzi MP, Lamberti G, La Salvia A. Chemotherapy in well Differentiated\u2002Neuroen- docrine\u2002tumors (NET)\u2002G1,\u2002G2, and\u2002G3: A narrative review. J Clin Med. 2023;12(2):717.","journal-title":"J Clin Med"},{"issue":"12","key":"1824_CR4","doi-asserted-by":"publisher","first-page":"2679","DOI":"10.1002\/ijc.30400","volume":"139","author":"M Riihim\u00e4ki","year":"2016","unstructured":"Riihim\u00e4ki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. The epidemiology of metastases in\u2002neuroendocrine\u2002tumors. Int J Cancer. 2016;139(12):2679\u201386.","journal-title":"Int J Cancer"},{"issue":"3","key":"1824_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1007\/s00261-018-1803-x","volume":"44","author":"S Ren","year":"2019","unstructured":"Ren S, Chen X, Wang J, Zhao R, Song L, Li H, Wang Z. Differentiation of duodenal Gastrointestinal stromal tumors from hypervascular pancreatic neuroendocrine tumors in the pancreatic head using contrast-enhanced computed tomography. Abdom Radiol (NY). 2019;44(3):867\u201376.","journal-title":"Abdom Radiol (NY)"},{"key":"1824_CR6","doi-asserted-by":"crossref","unstructured":"Chauhan A, Chan K, Halfdanarson TR, Bellizzi AM, Rindi G, O\u2019Toole D, Ge PS, Jain D, Dasari A, Anaya DA, Bergsland E, Mittra E, Wei AC, Hope TA, Kendi AT, Thomas SM, Flem S, Brierley J, Asare EA, Washington K, Shi C. Critical updates in neuroendocrine tumors: version 9 American joint committee on Cancer staging system for gastroenteropancreatic neuroendocrine tumors. CA Cancer J Clin. 2024 Jul-Aug;74(4):359\u201367.","DOI":"10.3322\/caac.21840"},{"issue":"3","key":"1824_CR7","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/MED.0000000000000805","volume":"30","author":"IM Jacoba","year":"2023","unstructured":"Jacoba IM, Weber HC. Biomarkers in gastroenteropancreatic neuroendocrine neoplasms. Curr Opin Endocrinol Diabetes Obes. 2023;30(3):175\u201380.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"issue":"6","key":"1824_CR8","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.4251\/wjgo.v15.i6.1051","volume":"15","author":"S Ren","year":"2023","unstructured":"Ren S, Guo K, Li Y, Cao YY, Wang ZQ, Tian Y. Diagnostic accuracy of apparent diffusion coefficient to differentiate intrapancreatic accessory spleen from pancreatic neuroendocrine tumors. World J Gastrointest Oncol. 2023;15(6):1051\u201361.","journal-title":"World J Gastrointest Oncol"},{"issue":"2","key":"1824_CR9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2214\/AJR.18.19881","volume":"211","author":"Y Sanli","year":"2018","unstructured":"Sanli Y, Garg I, Kandathil A, Kendi T, Zanetti MJB, Kuyumcu S, Subramaniam RM. Neuroendocrine\u2002Tumor diagnosis and Management:\u200268Ga-DOTATATE P- ET\/CT. AJR Am J Roentgenol. 2018;211(2):267\u201377.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"1824_CR10","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s11864-022-00967-z","volume":"23","author":"E Fortunati","year":"2022","unstructured":"Fortunati E, Argalia G, Zanoni L, Fanti S, Ambrosini V. New\u2002PET\u2002Radiotra- Cers for the imaging of\u2002neuroendocrine\u2002neoplasms. Curr Treat Options Oncol. 2022;23(5):703\u201320.","journal-title":"Curr Treat Options Oncol"},{"issue":"8","key":"1824_CR11","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1007\/s00259-023-06200-9","volume":"50","author":"D Chen","year":"2023","unstructured":"Chen D, Yang S, Chen J, Li T, Liu Y, Zhao X, Zhang T, Xu M, Wang H, Zhao K, Su X. Comparison of [18F]-OC\u2002PET\/CT\u2002and contrast-enhanced\u2002CT\/MRI in the detection and evaluation of\u2002neuroendocrine\u2002neoplasms. Eur J Nucl Med Mol Imaging. 2023;50(8):2420\u201331.","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"6","key":"1824_CR12","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1097\/RLU.0000000000002578","volume":"44","author":"T Long","year":"2019","unstructured":"Long T, Yang N, Zhou M, Chen D, Li Y, Li J, Tang Y, Liu Z, Li Z, Hu S. Clinical application of [18F]AlF-NOTA-Octreotide PET\/CT in combination with [18F]FDG PET\/CT for imaging neuroendocrine neoplasms. Clin Nucl Med. 2019;44(6):452\u20138.","journal-title":"Clin Nucl Med"},{"issue":"20","key":"1824_CR13","doi-asserted-by":"publisher","first-page":"6818","DOI":"10.3390\/molecules27206818","volume":"27","author":"JH Dam","year":"2022","unstructured":"Dam JH, Langkj\u00e6r N, Baun C, Olsen BB, Nielsen AY, Thisgaard H. Preparation and evaluation of [18F]AlF-NOTA-NOC for PET imaging of neuroendocrine tumors: comparison to [68Ga]Ga-DOTA\/NOTA-NOC. Molecules. 2022;27(20):6818.","journal-title":"Molecules"},{"issue":"13","key":"1824_CR14","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.7150\/thno.75336","volume":"12","author":"S Ahenkorah","year":"2022","unstructured":"Ahenkorah S, Murce E, Cawthorne C, et al. 3p-C-NETA: A versatile and effective chelator for development of Al\u2009<\u2009sup\u2009>\u200918\u2009F-labeled and therapeutic radiopharmaceuticals. Theranostics. 2022;12(13):5971\u201385. Published 2022.","journal-title":"Theranostics"},{"key":"1824_CR15","doi-asserted-by":"crossref","unstructured":"Hou G, Cheng X, Jiang Y, Zheng R, Wang X. A Rare Case of Peritoneal Mesothelioma Detected by 18 F-AlF-NOTA-Octreotide PET\/CT. Clin Nucl Med. 2025;50(5):446\u20137","DOI":"10.1097\/RLU.0000000000005681"},{"issue":"3","key":"1824_CR16","doi-asserted-by":"publisher","first-page":"454","DOI":"10.2967\/jnumed.109.066902","volume":"1","author":"P Laverman","year":"2010","unstructured":"Laverman P, McBride WJ, Sharkey RM, Eek A, Joosten L, Oyen WJ. Golden- Berg DM, Boerman OC.A novel facile method of labeling octreotide with (18) F- fluorine. J Nucl Med. 2010;1(3):454\u201361.","journal-title":"J Nucl Med"},{"issue":"9","key":"1824_CR17","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.2967\/jnumed.111.088906","volume":"52","author":"J Leyton","year":"2011","unstructured":"Leyton J, Iddon L, Perumal M, Indrevoll B, Glaser M, Robins E, George AJ, Cuthbertson A, Luthra SK, Aboagye EO. Targeting somatostatin receptors: preclinical evaluation of novel [18F] fluoroethyltriazole-Tyr3-octreotate analogs for PET. J Nucl Med. 2011;52(9):1441\u20138.","journal-title":"J Nucl Med"},{"issue":"2","key":"1824_CR18","doi-asserted-by":"publisher","first-page":"111","DOI":"10.5603\/NMR.2016.0022","volume":"19","author":"J Hankus","year":"2016","unstructured":"Hankus J, Tomaszewska R. Neuroendocrine neoplasms and somatostatin receptor\u2002subtypes\u2002expression. Nucl Med Rev Cent East Eur. 2016;19(2):111\u20137.","journal-title":"Nucl Med Rev Cent East Eur"},{"key":"1824_CR19","doi-asserted-by":"crossref","unstructured":"Shi M, Zhou B. Clinical characteristics and prognostic factors of early-onset pancreatic neuroendocrine tumors. Cancer Control. 2021 Jan-Dec; 28:1073274820986827.","DOI":"10.1177\/1073274820986827"},{"issue":"4","key":"1824_CR20","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1016\/j.suc.2019.04.014","volume":"99","author":"AT Scott","year":"2019","unstructured":"Scott AT, Howe JR. Evaluation and management of neuroendocrine tumors of the pancreas. Surg Clin North Am. 2019;99(4):793\u2013814.","journal-title":"Surg Clin North Am"},{"issue":"970","key":"1824_CR21","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1259\/bjr\/26210052","volume":"81","author":"M Gorenberg","year":"2008","unstructured":"Gorenberg M, Bar-Shalom R, Israel O. Patterns of FDG uptake in post-thoracotomy surgical scars in patients with lung cancer. Br J Radiol. 2008;81(970):821\u20135.","journal-title":"Br J Radiol"},{"issue":"2","key":"1824_CR22","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1007\/s12020-022-03000-3","volume":"76","author":"L Magi","year":"2022","unstructured":"Magi L, Prosperi D, Lamberti G, Marasco M, Ambrosini V, Rinzivillo M, Campana D, Gentiloni G, Annibale B, Signore A, Panzuto F. Role of [18F]FDG PET\/CT in the management of G1 gastro-entero-pancreatic neuroendocrine tumors. Endocrine. 2022;76(2):484\u201390.","journal-title":"Endocrine"},{"issue":"1","key":"1824_CR23","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11605-014-2624-z","volume":"19","author":"T Curran","year":"2015","unstructured":"Curran T, Pockaj BA, Gray RJ, Halfdanarson TR, Wasif N. Importance of lymph node involvement in pancreatic neuroendocrine tumors: impact on survival and implications for surgical resection. J Gastrointest Surg. 2015;19(1):152\u201360.","journal-title":"J Gastrointest Surg"},{"issue":"2","key":"1824_CR24","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.jamcollsurg.2013.11.001","volume":"218","author":"M Qadan","year":"2014","unstructured":"Qadan M, Ma Y, Visser BC, Kunz PL, Fisher GA, Norton JA, Poultsides GA. Reassessment of the current American joint committee on Cancer staging system for pancreatic neuroendocrine tumors. J Am Coll Surg. 2014;218(2):188\u201395.","journal-title":"J Am Coll Surg"},{"issue":"1","key":"1824_CR25","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000457954","volume":"106","author":"M Scharf","year":"2018","unstructured":"Scharf M, Petry V, Daniel H, Rinke A, Gress TM. Bone metastases in patients with neuroendocrine neoplasm: frequency and clinical, therapeutic, and prognostic relevance. Neuroendocrinology. 2018;106(1):30\u20137.","journal-title":"Neuroendocrinology"},{"key":"1824_CR26","doi-asserted-by":"crossref","unstructured":"Zhang P, Yu J, Li J, Shen L, Li N, Zhu H, Zhai S, Zhang Y, Yang Z, Lu M. Clinical and Prognostic Value of PET\/CT Imaging with Combination of 68Ga-DOTATATE and [18F]FDG in Gastroenteropancreatic Neuroendocrine Neoplasms. Contrast Media Mol Imaging. 2018; 2018:2340389.","DOI":"10.1155\/2018\/2340389"},{"key":"1824_CR27","unstructured":"Lam AK, Ishida H. Pancreatic neuroendocrine neoplasms: Clinicopathological features and pathological staging. Histol Histopathol. 2021;36(4):367\u201382."},{"issue":"5","key":"1824_CR28","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/j.amjsurg.2023.08.011","volume":"226","author":"A Harrelson","year":"2023","unstructured":"Harrelson A, Wang R, Stewart A, Ingram C, Gillis A, Rose JB, El-Rayes B, Azmi A, Chen H. Management of neuroendocrine tumor liver metastases. Am J Surg. 2023;226(5):623\u201330.","journal-title":"Am J Surg"},{"issue":"3","key":"1824_CR29","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1159\/000508633","volume":"111","author":"M Cives","year":"2021","unstructured":"Cives M, Pell\u00e8 E, Rinzivillo M, Prosperi D, Tucci M, Silvestris F, Panzuto F. Bone metastases in neuroendocrine tumors: molecular pathogenesis and implications in clinical practice. Neuroendocrinology. 2021;111(3):207\u201316.","journal-title":"Neuroendocrinology"},{"key":"1824_CR30","doi-asserted-by":"publisher","first-page":"727327","DOI":"10.3389\/fendo.2021.727327","volume":"12","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Wang Z, Zhang B, Wu Y, Li G, Wang Z. Comparison of 68Ga-DOTANOC and [18F]FDG PET-CT scans in the evaluation of primary tumors and lymph node metastasis in patients with rectal neuroendocrine tumors. Front Endocrinol (Lausanne). 2021;12:727327.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"12","key":"1824_CR31","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.diii.2020.06.006","volume":"101","author":"A Azoulay","year":"2020","unstructured":"Azoulay A, Cros J, Vullierme MP, de Mestier L, Couvelard A, Hentic O, Ruszniewski P, Sauvanet A, Vilgrain V, Ronot M. Morphological imaging and CT histogram analysis to differentiate pancreatic neuroendocrine tumor grade 3 from neuroendocrine carcinoma. Diagn Interv Imaging. 2020;101(12):821\u201330.","journal-title":"Diagn Interv Imaging"},{"issue":"6","key":"1824_CR32","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1097\/RLI.0000000000000028","volume":"49","author":"EJ Hwang","year":"2014","unstructured":"Hwang EJ, Lee JM, Yoon JH, Kim JH, Han JK, Choi BI, Lee KB, Jang JY, Kim SW, Nickel MD, Kiefer B. Intravoxel incoherent motion diffusion-weighted imaging of pancreatic neuroendocrine tumors: prediction of the histologic grade using pure diffusion coefficient and tumor size. Invest Radiol. 2014;49(6):396\u2013402.","journal-title":"Invest Radiol"},{"issue":"4","key":"1824_CR33","doi-asserted-by":"publisher","first-page":"R153","DOI":"10.1530\/EJE-14-0173","volume":"171","author":"S Partelli","year":"2014","unstructured":"Partelli S, Maurizi A, Tamburrino D, Baldoni A, Polenta V, Crippa S, Falconi M. GEP-NETS update: a review on surgery of gastro-entero-pancreatic neuroendocrine tumors. Eur J Endocrinol. 2014;171(4):R153\u201362.","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"1824_CR34","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1097\/SLA.0b013e31815b9cae","volume":"247","author":"KY Bilimoria","year":"2008","unstructured":"Bilimoria KY, Talamonti MS, Tomlinson JS, Stewart AK, Winchester DP, Ko CY, Bentrem DJ. Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients. Ann Surg. 2008;247(3):490\u2013500.","journal-title":"Ann Surg"},{"issue":"1","key":"1824_CR35","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1007\/s00595-018-1703-2","volume":"49","author":"T Matsumoto","year":"2019","unstructured":"Matsumoto T, Okabe H, Yamashita YI, Yusa T, Itoyama R, Nakao Y, Yamao T, Umzaki N, Tsukamoto M, Kitano Y, Miyata T, Arima K, Nitta H, Hayashi H, Imai K, Chikamoto A, Baba H. Clinical role of Fludeoxyglucose (18F) positron emission tomography\/computed tomography ([18F]FDG PET\/CT) in patients with pancreatic neuroendocrine tumors. Surg Today. 2019;49(1):21\u20136.","journal-title":"Surg Today"}],"container-title":["BMC Medical Imaging"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12880-025-01824-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12880-025-01824-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,7]],"date-time":"2025-09-07T05:51:26Z","timestamp":1757224286000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedimaging.biomedcentral.com\/articles\/10.1186\/s12880-025-01824-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1824"],"URL":"https:\/\/doi.org\/10.1186\/s12880-025-01824-9","relation":{},"ISSN":["1471-2342"],"issn-type":[{"value":"1471-2342","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The research adhered to the Declaration of Helsinki and its latest amendments. The retrospective study was approved by the Ethics Committee of The first Affiliated Hospital, college of Medicine, Zhejiang University (NO: IIT202110004C-R1). Written informed consent was obtained from all patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"280"}}